FR2173988A1 - - Google Patents

Info

Publication number
FR2173988A1
FR2173988A1 FR7303843A FR7303843A FR2173988A1 FR 2173988 A1 FR2173988 A1 FR 2173988A1 FR 7303843 A FR7303843 A FR 7303843A FR 7303843 A FR7303843 A FR 7303843A FR 2173988 A1 FR2173988 A1 FR 2173988A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7303843A
Other languages
French (fr)
Other versions
FR2173988B1 (ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of FR2173988A1 publication Critical patent/FR2173988A1/fr
Application granted granted Critical
Publication of FR2173988B1 publication Critical patent/FR2173988B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR7303843A 1972-02-04 1973-02-02 Expired FR2173988B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22372372A 1972-02-04 1972-02-04
US29145072A 1972-09-22 1972-09-22

Publications (2)

Publication Number Publication Date
FR2173988A1 true FR2173988A1 (ko) 1973-10-12
FR2173988B1 FR2173988B1 (ko) 1976-10-22

Family

ID=26918072

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7303843A Expired FR2173988B1 (ko) 1972-02-04 1973-02-02

Country Status (9)

Country Link
JP (1) JPS5623994B2 (ko)
AU (1) AU475978B2 (ko)
BE (1) BE794964A (ko)
CA (1) CA1009652A (ko)
DE (1) DE2305575A1 (ko)
FR (1) FR2173988B1 (ko)
GB (1) GB1418822A (ko)
HK (1) HK15581A (ko)
YU (2) YU210773A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422649A1 (fr) * 1978-04-10 1979-11-09 Bristol Myers Co Iminoquinazolines et leur utilisation a la preparation de la 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazoline-2(3h)-one

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
CZ281628B6 (cs) * 1991-07-29 1996-11-13 Warner-Lambert Company Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
US5849741A (en) * 1994-08-09 1998-12-15 Eisai Co., Ltd. Fused pyridazine compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
PT3004138T (pt) 2013-06-05 2024-06-18 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN117062819A (zh) * 2021-03-23 2023-11-14 北京生命科学研究所 多环化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081375A1 (ko) * 1969-12-18 1971-12-03 Smith Kline French Lab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2081375A1 (ko) * 1969-12-18 1971-12-03 Smith Kline French Lab

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422649A1 (fr) * 1978-04-10 1979-11-09 Bristol Myers Co Iminoquinazolines et leur utilisation a la preparation de la 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazoline-2(3h)-one

Also Published As

Publication number Publication date
YU210773A (en) 1983-02-28
DE2305575C2 (ko) 1989-01-12
AU475978B2 (en) 1976-09-09
DE2305575A1 (de) 1973-08-09
JPS4886894A (ko) 1973-11-15
HK15581A (en) 1981-05-01
YU151081A (en) 1983-12-31
GB1418822A (en) 1975-12-24
BE794964A (fr) 1973-08-02
FR2173988B1 (ko) 1976-10-22
JPS5623994B2 (ko) 1981-06-03
CA1009652A (en) 1977-05-03
AU5166873A (en) 1974-08-01

Similar Documents

Publication Publication Date Title
FR2202160B1 (ko)
FR2173988B1 (ko)
JPS4991971A (ko)
JPS4990188A (ko)
JPS4926531A (ko)
JPS5345484B2 (ko)
JPS499834A (ko)
FR2199185B3 (ko)
JPS5327687B2 (ko)
JPS4983903U (ko)
JPS5235382Y2 (ko)
JPS4949639U (ko)
JPS4921774U (ko)
JPS4966452U (ko)
JPS4888135A (ko)
JPS48114053U (ko)
HU167227B (ko)
FR2187613A2 (ko)
CH559551A5 (ko)
CH584001A5 (ko)
CH562540A5 (ko)
CH560097A5 (ko)
CH560090A5 (ko)
CH560012A5 (ko)
CH559991A5 (ko)